Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for clascoterone cream 1% for the treatment of acne.
Clascoterone, a potential first-in-class topical androgen receptor inhibitor, targets androgen receptors at the application site, inhibiting the local effects of dihydrotestosterone, a key driver of acne lesion development.
The NDA includes data from two phase 3 trials that showed treatment with clascoterone was associated with a statistically significant improvement in all primary end points (success rate in Investigator’s Global Assessment [IGA], change from baseline in non-inflammatory lesion counts, change from baseline in inflammatory lesion counts).
As for safety, results from an open-label study showed no hormonal imbalance with clascoterone even after long-term treatment or when used on an enlarged application surface. Dermal adverse events associated with therapy included erythema/reddening on the face and trunk and scaling/dryness on the face.
“We look forward to working closely with FDA during the review process. If approved, clascoterone cream 1% will be the first new mechanism of action in the treatment of acne in nearly 40 years, offering dermatologists and patients a new and effective therapeutic alternative,” said Diana Harbort, CEO of Cassiopea.
The FDA has set a Prescription Drug User Fee Act action date of August 27, 2020 for the application.
For more information visit cassiopea.com.
